Conatus Pharmaceuticals Inc. (CNAT) announced after the close Wednesday that it Phase IIb trial of Emricasan in post-orthotopic liver transplant recipients failed to meet its primary endpoint.
from RTT - Before the Bell https://ift.tt/2H3vF1i
via IFTTT
No comments:
Post a Comment